Via the Diflucan® Partnership Program,  Pfizer's (link to Pfizer company page) antifungal medicine, Diflucan®(fluconazole), is made available free of charge for the treatment of Cryptococcal meningitis and esophageal candidiasis, two opportunistic infections associated with HIV/AIDS.

The program is open to governments and non-governmental organizations in developing countries.

Countries with HIV/AIDS prevalence greater than 1 percent will be given priority.

Cryptococcal meningitis is an infection of the lining of the brain that afflicts approximately 10 percent of AIDS patients. Esophageal candidiasis is an infection of the esophagus that afflicts an estimated 30 percent of AIDS patients.

The program includes not only the provision of Diflucan® through these institutions, but also provides training materials for health professionals in the diagnosis and treatment of opportunistic infections, as well as in inventory management for the program.

For more information, please see www.diflucanpartnership.org